Wire · opportunities
Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
Eli Lilly secured FDA approval to expand Mounjaro's label to reduce major adverse cardiovascular events in adults with Type 2 diabetes, matching a similar 2020 approval achieved by Novo Nordisk for Ozempic.
This Wire brief sits within Fusion42's coverage of Health, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You must now factor Mounjaro into competitive diabetic heart treatment options as Lilly’s label expansion sets a new standard with head-to-head trial proof. This opens a door to reevaluate partnerships and pipeline priorities against an incumbent attacking both diabetes and cardiovascular risk.
◆ Coverage
20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026
◆ Topics